Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Notice of results Press Release, Financial Results 10 February 2025 Notice of results
- Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE Press Release, Business Development 30 January 2025 Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE
- Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg Press Release, Product 14 January 2025 Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
- Hikma launches Meropenem for Injection, USP in the US Press Release, Product 14 January 2025 Hikma launches Meropenem for Injection, USP in the US
